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Psoriatic arthritis
AbstrAct
Objectives to compare baseline characteristics between 
patients with psoriatic arthritis (Psa) who achieved and did 
not achieve minimal disease activity (MDa) with biologic 
therapy in the US-based corrona Psoriatic arthritis/
Spondyloarthritis registry.
Methods Patients with Psa aged ≥18 years enrolled 
between March 2013 and March 2016 who were 
receiving biologics at enrolment (baseline), not in MDa 
and had ≥2 follow-up visits were included. Patients 
were classified as those who remained on their index 
biologic and achieved MDa at the second follow-up 
visit (MDa achievers (MDa-a)) and those who did not 
(MDa non-achievers (MDa-na)). Demographics, clinical 
characteristics, patient-reported outcomes and medication 
history were compared between groups.
Results Of 148 patients with Psa who met the inclusion 
criteria, 34 (23.0%) and 114 (77.0%) were classified 
as MDa-a and MDa-na, respectively. at baseline, most 
patients (96.6%) were receiving tumour necrosis factor 
inhibitors, and both groups were similar in age, sex, race, 
medication history, enthesitis and dactylitis counts, disease 
duration and comorbidities. compared with MDa-a, 
MDa-na had significantly worse mean tender joint count 
(7.2 vs 3.4), patient-reported pain (51.2 vs 35.7), patient-
reported fatigue (54.1 vs 42.4), physical function (Health 
assessment Questionnaire, 1.0 vs 0.6), Bath ankylosing 
Disease activity index (5.0 vs 3.4) and Bath ankylosing 
Spondylitis Functional index (4.0 vs 2.0) scores (all 
p<0.05).
Conclusions approximately one in four patients achieved 
MDa with their index biologic at the time of the second 
follow-up visit. Both groups were similar in several 
baseline demographic and clinical features; however, 
patients who did not achieve MDa generally had worse 
tender joint counts and patient-reported outcomes.
InTROduCTIOn
Psoriatic arthritis (PsA) is a chronic inflam-
matory disease of the skin and musculoskel-
etal system with an estimated prevalence 
of 0.1%–1.0%.1 PsA is closely associated 
with psoriasis; estimates indicate that up to 
one-third of patients with psoriasis develop 
PsA.2 3 A heterogeneous condition, PsA is 
often characterised by axial skeleton disor-
ders, nail and skin changes, peripheral 
joint inflammation, enthesitis and dactylitis, 
Key messages
What is already known about this subject?
 ► international treatment guidelines developed by the 
group for research and assessment of Psoriasis 
and Psoriatic arthritis and the european league 
against rheumatism indicate that the goal of 
treatment should be to achieve the lowest possible 
disease activity across all domains, targeting 
remission or minimal/low disease activity.
 ► Biologic therapies are approved for the treatment 
of psoriatic arthritis (Psa) and have demonstrated 
efficacy in treating all Psa manifestations; however, 
patient responses to these therapies vary.
What does this study add?
 ► Seventy-seven per cent of patients with Psa did not 
achieve minimal disease activity (MDa; defined as 
meeting ≥5 of the seven following criteria: tender 
joint count ≤1, swollen joint count ≤1, affected body 
surface area ≤3%, patient pain visual analogue 
scale ≤15, patient global activity visual analogue 
scale ≤20, Health assessment Questionnaire 
score ≤0.5 and tender entheseal points ≤1) with 
their index biologic therapy at the time of the 
second follow-up visit (mean, 15.7 months).
 ► although MDa achievers and MDa non-achievers 
were similar in several baseline demographic and 
clinical characteristics, non-achievers had higher 
tender joint counts and significantly worse patient-
reported outcomes.
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present either in isolation or in combination with each 
other.2 In addition, patients with PsA may have other 
comorbidities that contribute to psychological and phys-
ical function impairment and increase their clinical and 
quality-of-life burden.4 The heterogeneity of disease can 
complicate treatment choices.5 Deeper insight into the 
immunopathogenesis of PsA has resulted in the introduc-
tion of novel therapeutic agents and strategies that have 
improved patient outcomes.
Selecting the most appropriate treatment for PsA can be 
challenging. International guidelines have been developed 
by the Group for Research and Assessment of Psoriasis 
and Psoriatic Arthritis and the European League Against 
Rheumatism.6 7 Both groups indicate the goal of treat-
ment should be to achieve the lowest possible levels of 
disease activity across all domains, with a target of remis-
sion, if possible, or minimal/low disease activity.6 7 As the 
first biologic therapies approved for the treatment of PsA, 
tumour necrosis factor inhibitors (TNFi) showed superior 
efficacy versus placebo in treating all manifestations of PsA, 
including arthritis, enthesitis, dactylitis, spondylitis, skin 
and nail disease, inflammatory bowel disease and uveitis.8–12 
However, not all patients with PsA respond to TNFis, and 
some patients may have contraindications to the use of 
these agents; therefore, some patients may switch to agents 
with a different mode of action. Several non-TNFi biologics 
and targeted synthetic disease-modifying antirheumatic 
drugs (DMARD) have been approved by the US Food and 
Drug Administration for the treatment of PsA, including 
monoclonal antibodies targeting interleukin (IL)-17A13–16 
and IL-12/23,17 18 a T-cell costimulation modulator,19 an 
oral phosphodiesterase 4 inhibitor20–22 and an oral Janus 
kinase inhibitor.23 24
Although several biologic therapies have been studied 
in clinical trials of PsA, results in patients enrolled in clin-
ical trials are not necessarily generalisable to real-world 
clinical settings, where patients may present with a wider 
spectrum of disease, have multiple comorbidities and may 
have very different treatment histories. Investigation of 
the reasons behind varying responses to biologic therapy 
is an unmet need in the field. In this study, we sought to 
characterise patients with PsA based on response to their 
index biologic using data from the Corrona Psoriatic 
Arthritis/Spondyloarthritis (PsA/SpA) Registry, a large, 
national prospective cohort of patients with PsA and SpA 
in the USA.
MeThOds
study design
The Corrona PsA/SpA Registry is a large, independent, 
prospective observational cohort of patients with PsA or 
SpA. The Corrona PsA/SpA Registry database includes 
information about 10 174 patient visits, with a mean dura-
tion of patient follow-up of 2.8 years (median, 3.1 years). 
As of November 2017, data on 2445 patients with PsA/
SpA had been collected from 32 private and academic 
practice sites across 21 states in the USA, with 42 partic-
ipating rheumatologists. This study included all patients 
with PsA enrolled in the Corrona PsA/SpA Registry 
between March 2013 and March 2016 who initiated or 
were already receiving biologics and/or targeted synthetic 
DMARDs (index biologic), including a monoclonal 
antibody targeting IL-12/23 and a phosphodiesterase 4 
inhibitor, at enrolment (baseline) and had ≥2 follow-up 
visits after enrolment at ≈6-month intervals.
Patients were stratified based on their response to their 
index biologic and were classified based on achievement 
of minimal disease activity (MDA) while persisting on their 
index biologic therapy. Achievement of MDA occurred 
if a patient met ≥5 of the seven following criteria25: 
tender joint count ≤1, swollen joint count ≤1, affected 
body surface area (BSA) ≤3%, patient pain on a visual 
analogue scale (VAS) ≤15, patient global activity VAS ≤20, 
Health Assessment Questionnaire (HAQ) score ≤0.5 and 
tender entheseal points ≤1. For the purpose of this study, 
patients who achieved MDA and who were still on their 
index biologic therapy at the time of the second follow-up 
visit were classified as MDA achievers (MDA-A). Patients 
who discontinued their index biologic at any time prior 
to their second follow-up visit or did not achieve MDA 
at their second follow-up visit were classified as MDA 
non-achievers (MDA-NA).
study assessments and outcomes
Data were collected using provider and patient question-
naires from treating rheumatologists and patients at routine 
visits occurring at 6-month intervals, not to exceed two visits 
in any 12-month period. All assessments, including demo-
graphics, current and prior medication use, clinical charac-
teristics and patient-reported outcomes, were collected at 
baseline. Specifically, information was collected for patient 
demographics (eg, age, sex, race, body mass index (BMI)); 
current and prior medication use (eg, biologics, conven-
tional synthetic DMARDs, targeted synthetic DMARDs 
and prednisone); clinical characteristics including clinical 
features (eg, disease duration, human leukocyte antigen 
(HLA)-B27 test results, history of comorbidities, enthesitis, 
dactylitis, affected BSA and tender and swollen joint 
counts), laboratory measurements (eg, C-reactive protein 
(CRP) and erythrocyte sedimentation rate), disease activity 
measures (eg, physician global skin assessment, Clinical 
Disease Activity Index (CDAI), Bath Ankylosing Disease 
Activity Index (BASDAI), Disease Activity Score in 28 
joints using CRP (DAS28-CRP) and Ankylosing Spondylitis 
Disease Activity Score using CRP (ASDAS-CRP)), physical 
Key messages
how might this impact on clinical practice?
 ► early detection of patients who do not achieve a response to 
their index biologic therapy prevents delays in optimising patient 
care and disease management, which may be improved by more 
thorough examination of patients and a better understanding of 
disease features, as well as striving to achieve a treatment target 
such as MDa.
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function measures (eg, Bath Ankylosing Spondylitis Func-
tional Index (BASFI) and HAQ), spinal mobility measures 
(eg, occiput-to-wall distance, lateral lumbar flexion); and 
patient-reported outcomes (eg, patient-reported pain and 
fatigue as measured on a VAS, morning stiffness measured 
in minutes, quality of life using the EQ-5D-3L and Work 
Productivity and Activity Impairment questionnaire).
Physician-reported reasons for discontinuation or 
switch of the index biologic therapy (side effects, social 
reasons, lack of effect, doing well and other) by the 
second follow-up visit were described for MDA-NA. Side 
effects included both serious and minor as well as a fear 
of side effects; social reasons included cost of, prefer-
ence for and frequency of treatment administration; lack 
of effects included inadequate response and failure to 
maintain initial response; doing well included achieve-
ment of remission and other similar events; and other 
was inclusive of all other reasons that could not other-
wise be categorised. Up to three reasons for treatment 
discontinuation or switch could have been captured on 
follow-up physician questionnaires.
data analysis
Descriptive analyses of patient demographics, clinical 
characteristics, patient-reported outcomes and medica-
tion history were conducted for all patients with PsA who 
had been enrolled in Corrona at baseline and stratified 
by their response to index biologic therapy. Response 
to a biologic was measured at the second follow-up visit 
from baseline, as described above.
Categorical variables (eg, sex, race, BMI, prevalence of 
comorbidities) were summarised using frequency counts 
and percentages. Continuous variables (eg, age, clinical 
measures and disease measures) were summarised by the 
counts and mean (SD). Statistical comparisons between 
response groups were evaluated using t-tests for contin-
uous variables and χ2 tests or Fisher’s exact tests for 
categorical variables. All analyses were performed using 
STATA V.13.
ResulTs
Patient population and baseline patient characteristics
Of the 1729 patients with PsA in the Corrona PsA/SpA 
Registry, 969 received a biologic at baseline (ie, patients 
who initiated a biologic or were already receiving a 
biologic at the baseline visit). Of these patients, 489 
had ≥2 follow-up visits, with 322 patients who had enough 
information to determine MDA status both at base-
line and at the second follow-up visit. The 174 patients 
who were in MDA at baseline were excluded, resulting 
in 148 patients who met the criteria for achievement/
non-achievement of MDA and were included in this anal-
ysis (figure 1). At the time of the second follow-up visit 
(mean, 15.7 months), 34 patients (23.0%) remained on 
their index biologic, had achieved MDA and were cate-
gorised as MDA-A; the remaining 114 patients (77.0%) 
were labelled as MDA-NA. Among the 114 patients who 
were classified as MDA-NA, 44 had discontinued their 
index therapy or been switched to another biologic by 
the second follow-up visit. Of these 44 patients, 15 had 
physician-reported reasons for discontinuation/switch, 
which were categorised as lack of effect (n=9), side effects 
(n=3), social reasons (n=1), doing well (n=1) and other 
(n=1) (figure 2).
At baseline, MDA-A and MDA-NA were similar across 
all demographic and patient characteristics, including 
age, sex, BMI, disease duration and history of comor-
bidities (eg, cardiovascular disease, diabetes, cancer 
and serious infection) (table 1). Past and current use 
of biologics was similar between MDA-A and MDA-NA, 
with a mean number of 1.4 prior biologics used; nearly 
all patients (96.6%) received a TNFi as their index 
biologic therapy while the remaining 3.4% received an 
anti-IL-12/23 monoclonal antibody or an oral phospho-
diesterase 4 inhibitor. Among those that initiated TNFis 
as their index biologic therapy, MDA-NA had a higher 
proportion of initiations prior to baseline compared with 
MDA-A (96.3% vs 84.9%; p<0.05).
Clinical characteristics
Overall, MDA-A and MDA-NA were mostly similar with 
regard to most clinical characteristics and measures of 
disease activity (table 2). There were no significant differ-
ences between MDA-NA and MDA-A for enthesitis counts 
(mean, 4.4 vs 2.4), dactylitis counts (mean, 2.4 vs 2.4) or 
swollen joint counts (mean, 2.8 vs 2.5); however, MDA-NA 
had a significantly higher tender joint count at baseline 
than MDA-A (mean, 7.2 vs 3.4; p<0.05). Despite the differ-
ences in tender joint counts, there was no between-group 
difference for CDAI, which incorporates tender/swollen 
joint counts and patient/physician global disease activity 
(mean, 14.0 vs 12.8 for MDA-NA and MDA-A, respec-
tively). There were no significant differences between 
groups in acute-phase reactants, which is also reflected 
in disease activity scores that include a CRP component 
(mean DAS28-CRP, 3.2 vs 3.1 and mean ASDAS-CRP, 2.2 
vs 1.9 for MDA-NA and MDA-A, respectively). However, 
MDA-NA had significantly worse spondyloarthritides-re-
lated disease activity and function at baseline than 
MDA-A, as assessed by BASDAI (mean, 5.0 vs 3.4) and 
BASFI (mean, 4.1 vs 2.0; both p<0.05).
Patient-reported outcomes
Although clinical characteristics were mostly similar in 
MDA-A and MDA-NA, patient-reported outcomes were 
significantly worse at baseline in patients who did not 
achieve MDA with their index biologic (table 3). There 
were no differences between groups in the proportion of 
patients who experienced ≥30 min of morning stiffness; 
however, compared with MDA-A, MDA-NA reported 
significantly worse pain (mean, 51.2 vs 35.7; p<0.05), 
physical function (mean HAQ, 1.0 vs 0.6) and quality of 
life (mean EQ-5D-3L, 0.7 vs 0.8; all p<0.05) at baseline. 
Work productivity and activity were reduced in MDA-NA; 
at baseline, MDA-NA reported significantly higher 
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percentages than MDA-A in impairment while working 
(27.4% vs 15.8%), overall work impairment (32.1% vs 
17.5%) and overall activity impairment (32.9% vs 18.8%; 
all p<0.05). However, although MDA-NA had a higher 
percentage of work time missed compared with MDA-A 
(6.1% vs 1.4%), this was not statistically significant.
dIsCussIOn
In this study, 23.0% of patients achieved MDA with 
their index biologic therapy at the time of their second 
follow-up visit. Other observational studies and clinical 
trials have investigated achievement of MDA with biologic 
therapy over similar durations of follow-up.26–32 Unlike 
many of these other studies, in which most patients’ prior 
treatments were conventional DMARDs and/or non-ste-
roidal anti-inflammatory drugs, in our study, nearly all the 
patients were previously treated with biologics. Similar to 
our study, patients included in these studies were not in 
MDA at baseline. An observational study in the UK found 
that 60% of their patient population achieved MDA 
at ≥1 visit, and 34% of these achieved sustained MDA 
over consecutive visits for ≥12 months; 2% of their total 
patient population had prior TNFi therapy.26 An analysis 
of 226 TNFi-naive patients with PsA from the University 
of Toronto Psoriatic Arthritis Cohort found that 64% of 
patients achieved MDA within 1.3 years of follow-up.27 
A prospective observational study showed that 61% of 
patients treated with etanercept, adalimumab or goli-
mumab achieved MDA at 12 months,28 and a retrospective 
analysis conducted by the same study group found that 
43% of patients treated with subcutaneous etanercept, 
adalimumab or golimumab achieved sustained MDA for 
at least 12 months.29 A subanalysis of the Adalimumab 
Effectiveness in Psoriatic Arthritis Trial (ADEPT) showed 
Figure 1 Study flow chart for patient inclusion and exclusion. MDA, minimal disease activity; PsA, psoriatic arthritis.
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that 39% of adalimumab-treated patients achieved MDA 
at week 24.30 In RAPID-PsA, 38.8% of certolizumab 
pegol-treated patients achieved MDA at week 48 regard-
less of prior TNFi exposure; only 20% of patients in this 
study were previously treated with TNFis.31 Lastly, 42% 
of golimumab-treated patients achieved MDA by week 52 
in the GO-REVEAL study.32 Other studies have looked 
at achievement of MDA with TNFis; however, they have 
either focused on early PsA cohorts, the impact of obesity 
or they had much shorter follow-up than Corrona.33–35
Compared with MDA-NA, MDA-A exhibited signifi-
cantly reduced mean tender joint count, patient-re-
ported pain, patient-reported fatigue, physical function 
impairment, BASDAI score and BASFI score at baseline, 
suggesting that there may be detectable differences 
in our study population that contributed to failure to 
achieve MDA. We found that patients with oligoarthritis 
(≤4 swollen joints) at baseline were approximately twice 
as likely to achieve MDA at the second follow-up visit 
compared with patients who had polyarthritis, which is 
not surprising, as a swollen joint count of ≤1 is one of the 
criteria for achievement of MDA. It is also possible that 
worse scores of subjective components of MDA (eg, pain, 
patient global activity) could be driven by central sensiti-
sation. In our study, we found that 11 patients classified 
as MDA-NA had fibromyalgia at baseline compared with 
0 patient classified as MDA-A; however, the numbers were 
too small to detect any significant differences between 
response groups, and the binary of having fibromyalgia 
may not capture the relativity or degree of central sensi-
tisation, such as pain levels or tender joint counts. Addi-
tionally, since the majority of the patients in our study 
were previously treated with biologics, which may have 
included other TNFis, it is possible that some patients 
were already receiving their second, third or more TNFi 
at baseline and may have been more refractory to their 
index biologic than other patients who had received 
fewer biologics (and/or for a shorter duration) or who 
were biologic naive. Prolonged exposure to TNFis has 
been linked to attenuated response rates with each succes-
sive TNFi used.36–38 Although MDA-A and MDA-NA were 
similar with regard to the mean number of prior biologics 
used, we did not conduct subgroup analyses based on the 
number and type of previous biologics used in MDA-A 
versus MDA-NA. We also did not have information on 
reasons for discontinuation of biologics prior to enrol-
ment in the Corrona Registry, and therefore were unable 
to assess whether achievement of a response was influ-
enced by intolerance to or adverse events with previous 
treatment. Despite these potential differences, MDA-A 
and MDA-NA were similar with regard to age, sex, race, 
disease duration, prevalence of comorbidities, multiple 
clinical characteristics (eg, enthesitis and dactylitis 
counts) and prior/current medications at baseline.
Within the last few years, studies have examined 
predictors of response to biologic therapies in patients 
with PsA, with much of the emphasis on identification 
of genetic or protein biomarkers.39–43 A meta-analysis of 
clinical trials and observational studies concluded that 
although numerous factors were associated with better 
response to TNFis in patients with ankylosing spondylitis 
(eg, younger age, male sex, high baseline BASDAI and 
CRP, low baseline BASFI and HLA-B27 positivity), no 
predictors of response were identified for patients with 
PsA.39 In contrast, an analysis of the infliximab and goli-
mumab clinical trials demonstrated that increased CRP 
levels at baseline were predictive of improved therapeutic 
response at the time point specified by the primary end 
point40; in our analysis, MDA-A had a higher CRP level at 
baseline than MDA-NA, but this difference was not signif-
icant. In a separate study of 97 patients with PsA who 
received treatment with etanercept for ≥3 months, two 
different polymorphisms were identified from genomic 
DNA extracted from buccal epithelial cells that were 
predictive of poor response to treatment (improvement 
in Psoriatic Arthritis and Severity Index ≥75% after 12 
Figure 2 Reasons for discontinuation or switch of the index biologic therapy by the second follow-up visit.
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Table 1 Patient characteristics and medication history of MDA-A versus MDA-NA at baseline
Characteristic*
Overall
n=148
MDA-A†
n=34
MDA-NA
n=114 P values
Age (years) 54.7 (11) 54.8 (12.8) 54.7 (10.5) 0.99
Female, n (%) 80 (54.4) 15 (44.1) 65 (57.5) 0.17
Race, n (%) 0.44
  White 136 (95.1) 32 (94.1) 104 (95.4)
  Asian 3 (2.1) 1 (2.9) 2 (1.8)
  Pacific Islander 1 (0.7) 1 (2.9) 0 (0.0)
  Mixed race 2 (1.4) 0 (0.0) 2 (1.8)
  Other 1 (0.7) 0 (0.0) 1 (0.9)
BMI (kg/m2) 33.1 (7.6) 32.5 (7.1) 33.2 (7.8) 0.60
BMI (in kg/m2) classifications, n (%) 0.76
  Normal/underweight (<25.0) 13 (89.0) 2 (6.1) 11 (9.8)
  Overweight (25.0 to <30.0) 50 (34.5) 13 (39.4) 37 (33.0)
  Obese (≥30.0) 82 (56.6) 18 (54.6) 64 (57.1)
Disease duration (years) 11.8 (10.1) 11.6 (8.2) 11.9 (10.6) 0.48
HLA-B27 test result on record, n (%) 34 (23.0) 8 (23.5) 26 (22.8) 0.08
  Positive test result (in patients with test results on 
record), n (%)
9 (26.5) 0 (0.0) 9 (34.6)
History of comorbidities, n (%)
  Cardiovascular disease‡ 92 (62.2) 20 (58.8) 72 (63.2) 0.65
  Diabetes mellitus 19 (12.8) 5 (14.7) 14 (12.3) 0.71
  Any cancer§ 15 (10.1) 2 (5.9) 13 (11.4) 0.52
  Fibromyalgia 11 (7.4) 0 (0.0) 11 (9.7) 0.07
  Serious infections¶ 7 (4.7) 1 (2.9) 6 (5.3) 1.00
Prior medication use, n (%)
  Biologic therapy 140 (94.6) 30 (88.2) 110 (96.5) 0.08
  Mean (SD) number of prior biologics 1.4 (0.8) 1.4 (1.0) 1.4 (0.7) 0.74
  Prior biologics, n (%) 0.16
   0 8 (5.4) 4 (11.8) 4 (3.5)
   1 94 (63.5) 19 (55.9) 75 (65.8)
   2+ 46 (31.1) 11 (32.4) 35 (30.7)
  csDMARD therapy 113 (76.4) 26 (76.5) 87 (76.3) 0.99
  Prednisone 17 (11.5) 3 (8.8) 14 (12.3) 0.76
Current biologic/tsDMARD use, n (%)** 1.00
  TNFis 142 (96.6) 33 (97.1) 109 (96.5)
  Initiations at baseline 9 (6.3) 5 (15.1) 4 (3.7) 0.03
  Initiations prior to baseline 133 (93.7) 28 (84.9) 105 (96.3)
  Other biologics/tsDMARD 6 (3.4) 1 (2.9) 5 (3.5)
Current prednisone use, n (%) 8 (5.4) 1 (2.9) 7 (6.1) 0.68
*All values were calculated based on available data and are presented as ‘mean (SD)’ unless otherwise stated. All variables had <20% missing data.
†MDA-A were classified as those patients who remained on their index biologic and achieved MDA at the second follow-up visit. MDA was 
determined to have been achieved if a patient met ≥5 of the seven following categories [25]: tender joint count ≤1, swollen joint count ≤1, BSA ≤3%, 
patient pain VAS ≤15, patient global activity VAS ≤20, HAQ score ≤0.5 and tender entheseal points ≤1.
‡Combined histories of myocardial infarction, acute coronary syndrome, coronary artery disease, congestive heart failure, hypertension, 
hyperlipidaemia, peripheral artery disease, cardiac revascularisation procedure, ventricular arrhythmia, cardiac arrest, unstable angina, stroke, 
transient ischaemic attack, pulmonary embolism, carotid artery disease, deep vein thrombosis or other cardiovascular event.
§Excludes non-melanoma of the skin.
¶Includes those infections that lead to hospitalisation or intravenous antibiotics: joint/bursa, cellulitis, sinusitis, diverticulitis, sepsis, pneumonia 
bronchitis, gastroenteritis, meningitis, urinary tract infection, upper respiratory infection or infection of other specified site.
**Index biologic and tsDMARD therapies included adalimumab, apremilast, certolizumab pegol, etanercept, golimumab, infliximab and ustekinumab.
BMI, body mass index; BSA, body surface area; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HAQ, Health Assessment 
Questionnaire; HLA, human leukocyte antigen; MDA, minimal disease activity; MDA-A, minimal disease activity achievers; MDA-NA, minimal disease 
activity non-achievers; TNFi, tumour necrosis factor inhibitor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug; VAS, visual 
analogue scale.
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weeks)41; however, these data need to be validated in 
larger studies.
As with any observational study, there are limitations to 
our analysis. This was a descriptive analysis of the patients 
who subsequently achieved or did not achieve MDA with 
their index biologic therapy, using stringent criteria 
for a target of response (persistence on index biologic 
therapy for ≥2 follow-up visits and achievement of MDA). 
We chose MDA as a conservative estimate of response, 
with the understanding that there are likely patients 
who did not achieve MDA in this analysis but who are 
still satisfied with their treatment. The criteria selected 
for inclusion meant that only one-half of patients who 
received a biologic at baseline had ≥2 follow-up visits, and 
not everyone had enough clinical information to deter-
mine MDA status at baseline and the time of the second 
follow-up visit, limiting the sample size of the study. We 
did consider including all patients with ≥1 follow-up visit 
instead of ≥2 follow-up visits, but this did not increase 
the number of patients appreciably. The overall sample 
size was too small to only include those patients who 
initiated a biologic at the time of the enrolment visit. To 
compensate, the study population consisted of patients 
who either initiated a biologic at the enrolment visit or 
were already receiving a biologic therapy at time of enrol-
ment. Among patients who initiated TNFis, a significantly 
higher proportion of MDA-NA had initiated their index 
TNFi prior to baseline compared with MDA-A; therefore, 
Table 2 Disease measures of MDA-A versus MDA-NA at baseline
Characteristic*
Overall
n=148
MDA-A
n=34
MDA-NA
n=114 P values
Enthesitis, n (%) 47 (31.8) 7 (20.6) 40 (35.1) 0.11
  SPARCC Enthesitis Index (1–16) 4.2 (3.1) 2.4 (0.5) 4.4 (3.3) 0.20
Dactylitis, n (%) 20 (13.5) 6 (17.6) 14 (12.3) 0.42
  Dactylitis count (1–20) 2.4 (1.7) 2.4 (2.6) 2.4 (1.3) 0.21
BSA, % affected 7.7 (13.2) 5.6 (8.1) 8.3 (14.4) 0.31
Physician global skin assessment, n (%) 0.80
  Clear 36 (24.5) 10 (29.4) 26 (23.0)
  Almost clear 48 (32.6) 12 (35.3) 36 (31.9)
  Mild disease 44 (29.9) 9 (26.5) 35 (31.0)
  Moderate disease 14 (9.5) 3 (8.8) 11 (9.7)
  Severe disease 5 (3.4) 0 (0.0) 5 (4.4)
CDAI 13.7 (8.2) 12.8 (6.8) 14.0 (8.5) 0.44
Tender joint count (68) 6.3 (10.1) 3.4 (5.3) 7.2 (11) 0.02
Swollen joint count (66) 2.7 (3.7) 2.5 (3.5) 2.8 (3.7) 0.71
  Oligoarthritis, n (%)† 114 (78.1) 29 (87.9) 85 (75.2) 0.12
BASDAI (0–10) 4.6 (2.3) 3.4 (2.1) 5.0 (2.3) 0.001
BASFI (0–10) 3.6 (2.5) 2.0 (1.9) 4.1 (2.4) <0.001
Spinal mobility measures
  Occiput-to-wall distance (cm) 1.2 (2.1) 0.9 (1.8) 1.3 (2.3) 0.80
  Lateral lumbar flexion (cm)
   Left 16.5 (8.9) 15.5 (8.2) 16.9 (9.3) 0.97
   Right 16.4 (8.5) 17.2 (5.8) 16.1 (9.4) 0.20
DAS28-CRP 3.2 (0.9) 3.1 (0.9) 3.2 (0.9) 0.73
ASDAS-CRP 2.2 (0.9) 1.9 (0.8) 2.2 (1.0) 0.14
CRP (mg/L) 4.3 (10.9) 4.9 (10.3) 4.1 (11.1) 0.60
ESR (mm/hour) 17.1 (15.8) 16.0 (14.8) 17.5 (16.1) 0.88
*All values were calculated based on available data and are presented as ‘mean (SD)’ unless otherwise stated. All variables had <20% 
missing data except for SPARCC Enthesitis Index (n=37/47), ASDAS-CRP (n=85), CRP (n=94) and ESR (n=92).
†Oligoarthritis was defined as ≤4 swollen joints.
ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity 
Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BSA, body surface area; CDAI, Clinical Disease Activity Index; CRP, C-reactive 
protein; DAS28-CRP, Disease Activity Score in 28 joints using C-reactive protein; ESR, erythrocyte sedimentation rate; MDA, minimal disease 
activity; MDA-A, minimal disease activity achievers; MDA-NA, minimal disease activity non-achievers; SPARCC, Spondyloarthritis Research 
Consortium of Canada; VAS, visual analogue scale.
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some of the baseline measurements and assessments in 
this analysis may be affected by the duration of biologic 
use prior to enrolment (eg, clinical and disease activity 
measures and patient-reported outcomes). We also do 
not have information on the reasons for why biologic 
therapy was initiated, so there may be subgroups of 
patients in the study population who may or may not be 
more likely to achieve MDA with their index biologic. 
More data on the prescribing physicians, as well as the 
patient population, are needed to help address this 
question. Any differences between MDA-A and MDA-NA 
that were observed at registry enrolment should not be 
interpreted as predictive of any specific outcome. Future 
longitudinal analyses with larger sample sizes are needed 
to apply more rigorous statistical models that adjust for 
confounding variables (eg, fibromyalgia, the presence 
of oligoarthritis vs polyarthritis and prior biologic use at 
baseline) and determine which covariates contribute to 
achievement of MDA with biologic therapies.
This analysis of patients with PsA in the Corrona 
Registry is the first to describe baseline characteristics of 
patients who subsequently achieved or did not achieve 
MDA with their index biologic therapy. Importantly, this 
study addresses a knowledge gap for rheumatologists by 
providing valuable information on a US population of 
patients who are predominantly biologic experienced. 
Early identification of patients who do not appear to 
respond to their index biologic is critical to ensuring 
they are receiving optimal care and management of their 
disease. Early recognition of patients who do not achieve 
a treatment target, such as MDA, may prevent delays in 
clinical response and unnecessary treatment costs. Addi-
tional studies with larger sample sizes are needed to 
examine predictors of biologic response in patients with 
PsA.
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